SCHEMBL99419

SCHEMBL99419

COc1ccc(-c2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
MAPT P10636 4/20 0.57
KDM4E B2RXH2 1/20 0.57
TDP1 Q9NUW8 1/20 0.56
RAB9A P51151 6/20 0.53
NPC1 O15118 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MAPK1 P28482 2/20 0.53
AKR1C3 P42330 2/20 0.51
AKR1C2 P52895 2/20 0.51
CASP3 P42574 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
AKR1B10 O60218 1/20 0.48
AKR1B1 P15121 1/20 0.48
AKR1C4 P17516 1/20 0.48
AKR1C1 Q04828 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 3/20 0.47
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30115292 0.91 ALDH1A1 (0.52) ALDH1A1MAPTKDM4ETDP1RAB9A
SCHEMBL2336139 0.90 HTR7 (0.56) ALDH1A1MAPTKDM4ETDP1RAB9A
SCHEMBL9312797 0.87 ALDH1A1 (0.56) ALDH1A1MAPTKDM4ETDP1RAB9A
SCHEMBL11188343 0.87 HTR7 (0.54) ALDH1A1MAPTKDM4ETDP1RAB9A
SCHEMBL11452569 0.87 ALDH1A1 (0.59) ALDH1A1MAPTKDM4ETDP1RAB9A
SCHEMBL10340370 0.86 ALDH1A1 (0.61) ALDH1A1MAPTKDM4ETDP1RAB9A
SCHEMBL229065 0.85 CYP1A2 (0.50) ALDH1A1MAPTKDM4ERAB9ANPC1
SCHEMBL7468121 0.84 ALDH1A1 (0.49) ALDH1A1MAPTKDM4ETDP1RAB9A
SCHEMBL10558720 0.83 MAPT (0.59) ALDH1A1MAPTKDM4ETDP1RAB9A
SCHEMBL225789 0.83 GSTP1 (0.58) ALDH1A1MAPTKDM4ETDP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116253646-A Synthesis method and application of 2-nitro-1, 1' -biphenyl compound 湖南海利化工股份有限公司 2023-06-13 CN disclosed
CN-111450893-A Preparation of palladium-loaded quasi-MOF photocatalyst with special morphology and one-pot multi-step hydrogenation N-alkylation reaction 重庆工商大学 2020-07-28 CN disclosed
US-9072734-B2 Quaternary ammonium salt compounds TEIJIN PHARMA LIMITED (JP) 2015-07-07 US disclosed
EP-2426121-A1 QUATERNARY AMMONIUM SALT COMPOUND Teijin Pharma Limited (JP) 2012-03-07 EP disclosed
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS TEIJIN PHARMA LIMITED (JP) 2012-02-23 US disclosed
US-5948817-A Polycyclic ethyl alkylamide melatonergic agents BRISTOL-MYERS SQUIBB COMPANY (US) 1999-09-07 US disclosed
WO-1998038991-A1 POLYCYCLIC ETHYL ALKYLAMIDE MELATONERGIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS ADRB2, AGTR2, ADRB3 ALDH1A1 1896/4885MAPT 2879/4885KDM4E 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.